STORM Therapeutics Raises $12 Million in Series A Funding for Groundbreaking RNA Modifying Enzyme Therapies

STORM Therapeutics Limited has recently announced a significant funding milestone, successfully raising £12 million to further its groundbreaking work in biotechnology.

Renowned for creating innovative therapies that target RNA modifying enzymes (RMEs), STORM Therapeutics is at the forefront of a rapidly evolving field that encompasses more than 150 RNA modifications and roughly 300 RMEs, presenting a wealth of untapped therapeutic opportunities.

This investment will bolster the company's commitment to developing first-in-class small-molecule drug candidates aimed at addressing challenging areas such as oncology, inflammation, viral infections, and central nervous system disorders.

As part of its noteworthy pipeline, STORM is advancing its METTL3 inhibitor (STC-15), which has already received FDA approval for an Investigational New Drug (IND) application, marking it as the first RME inhibitor to enter clinical trials in cancer patients.

With ambitious plans to expand its pipeline further in 2023, the new funding will enable STORM to accelerate its IND-track activities and enhance its state-of-the-art drug discovery and RNA analytics platforms.

Operating from the Babraham Research Campus near Cambridge, UK, STORM Therapeutics benefits from a skilled R&D team and strategic collaborations with high-quality contract research organizations such as Evotec, allowing the company to maintain a cost-efficient and adaptable research model.

With this latest round of funding, STORM Therapeutics is well-positioned to make significant strides in the development of novel therapeutic solutions that could reshape treatment paradigms in oncology and beyond.